658 related articles for article (PubMed ID: 29196939)
21. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
22. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
23. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
24. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
Herrera-Martínez AD; Gahete MD; Sánchez-Sánchez R; Alors-Perez E; Pedraza-Arevalo S; Serrano-Blanch R; Martínez-Fuentes AJ; Gálvez-Moreno MA; Castaño JP; Luque RM
Clin Transl Gastroenterol; 2018 Oct; 9(10):196. PubMed ID: 30297816
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
27. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
Herrera-Martínez AD; Gahete MD; Sánchez-Sánchez R; Salas RO; Serrano-Blanch R; Salvatierra Á; Hofland LJ; Luque RM; Gálvez-Moreno MA; Castaño JP
Lung Cancer; 2017 Jul; 109():128-136. PubMed ID: 28577942
[TBL] [Abstract][Full Text] [Related]
28. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
[TBL] [Abstract][Full Text] [Related]
29. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
[TBL] [Abstract][Full Text] [Related]
30. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
31. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
[TBL] [Abstract][Full Text] [Related]
32. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
33. Role of Somatostatin Signalling in Neuroendocrine Tumours.
Rogoza O; Megnis K; Kudrjavceva M; Gerina-Berzina A; Rovite V
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163374
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
36. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
[TBL] [Abstract][Full Text] [Related]
37. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
38. Biotherapies for GEP-NETs.
Öberg K
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
[TBL] [Abstract][Full Text] [Related]
39. Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases.
Zimmermann N; Lazar-Karsten P; Keck T; Billmann F; Schmid S; Brabant G; Thorns C
Anticancer Res; 2016 Mar; 36(3):921-4. PubMed ID: 26976979
[TBL] [Abstract][Full Text] [Related]
40. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
